Do We Really Need to Keep Redesigning β2-agonists for the Management of Asthma?

E-ISSN： 1875-5704|12|1|9-15

ISSN： 1567-2018

Source： Current Drug Delivery, Vol.12, Iss.1, 2015-02, pp. : 9-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Schizophrenia: Do we really need placebo-controlled studies?

By Storosum J.G. Elferink A.J.A. van Zwieten B.J.

European Neuropsychopharmacology, Vol. 8, Iss. 4, 1998-12 ,pp. : 279-286

Elsevier

Access to resources Recommend Favorite

Long-Acting β-Agonists in Asthma Management: What is the Current Status?

By Mysore Satya

Drugs, Vol. 71, Iss. 16, 2011-11 ,pp. : 2091-2097

Adis International

Access to resources Recommend Favorite

Evaluation of combination long-acting β-2 agonists and inhaled glucocorticosteroids for treatment of asthma

By Kim Dennis Glaum Mark Lockey Richard

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 8, 2009-08 ,pp. : 933-940

Informa Healthcare

Access to resources Recommend Favorite

Patients with asthma should use intermediate-acting inhaled β 2 -agonists only on an as-needed basis

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 22, Iss. 1, 2006-01 ,pp. : 12-13

Adis International

Access to resources Recommend Favorite

Long-Acting β2-Agonists in Asthma: Not so SMART?

By Currie Graeme P.

Drug Safety, Vol. 29, Iss. 8, 2006-01 ,pp. : 647-656

Adis International

Access to resources Recommend Favorite